170 related articles for article (PubMed ID: 27318760)
1. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
[TBL] [Abstract][Full Text] [Related]
4. 9-Phenanthrol enhances the generation of an CD8
Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
[TBL] [Abstract][Full Text] [Related]
5. Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects.
Gogoll K; Stein P; Wei H; Schild H; Radsak M; Langguth P
Biopharm Drug Dispos; 2012 May; 33(4):218-28. PubMed ID: 22473646
[TBL] [Abstract][Full Text] [Related]
6. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
8. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
11. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
[TBL] [Abstract][Full Text] [Related]
12. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
13. Microemulsions based on TPGS and isostearic acid for imiquimod formulation and skin delivery.
Pescina S; Garrastazu G; Del Favero E; Rondelli V; Cantù L; Padula C; Santi P; Nicoli S
Eur J Pharm Sci; 2018 Dec; 125():223-231. PubMed ID: 30316975
[TBL] [Abstract][Full Text] [Related]
14. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
[TBL] [Abstract][Full Text] [Related]
15. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.
Papadavid E; Stratigos AJ; Falagas ME
Expert Opin Pharmacother; 2007 Aug; 8(11):1743-55. PubMed ID: 17685890
[TBL] [Abstract][Full Text] [Related]
17. Aldara activates TLR7-independent immune defence.
Walter A; Schäfer M; Cecconi V; Matter C; Urosevic-Maiwald M; Belloni B; Schönewolf N; Dummer R; Bloch W; Werner S; Beer HD; Knuth A; van den Broek M
Nat Commun; 2013; 4():1560. PubMed ID: 23463003
[TBL] [Abstract][Full Text] [Related]
18. Intradermal Delivery of an Immunomodulator for Basal Cell Carcinoma; Expanding the Mechanistic Insight into Solid Microneedle-Enhanced Delivery of Hydrophobic Molecules.
Sabri A; Ogilvie J; McKenna J; Segal J; Scurr D; Marlow M
Mol Pharm; 2020 Aug; 17(8):2925-2937. PubMed ID: 32510228
[TBL] [Abstract][Full Text] [Related]
19. Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer.
Rehman K; Zulfakar MH
Pharm Res; 2017 Jan; 34(1):36-48. PubMed ID: 27620176
[TBL] [Abstract][Full Text] [Related]
20. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
